Objective: We hypothesized that most patients with 22q11.2 deletion and a history of hypocalcemia have inadequate parathyroid function, manifested by intact parathyroid hormone levels below normal. We aimed to evaluate intact parathyroid hormone levels both during normocalcemia and at hypocalcemia, in this population.Study Design: Retrospective chart review of 103 patients with 22q11.2 deletion born since 1997 and cared for at the Children's Hospital of Philadelphia. Calcium and intact parathyroid hormone drawn simultaneously were recorded, along with clinical presentation at hypocalcemia. Results: Forty-seven simultaneous Ca/intact parathyroid hormone values were available. Seventy-nine percent of calcium levels and 81% of parathyroid hormone levels were within normal range. There were 19 patients with a history of symptomatic hypocalcemia, for whom any available simultaneous Ca/parathyroid hormone levels, before, during, or after hypocalcemia were analyzed. In this subgroup, 59% of calcium and 76% of parathyroid hormone levels were normal. None had an intact parathyroid hormone of Ͼ39.2 pg/mL at hypocalcemia. Seventy-three percent of hypocalcemic events had a precipitating stressor. Conclusions: Hypoparathyroidism in 22q11.2 deletion is mild, manifesting as a phenomenon of decreased parathyroid hormone reserve. Subjects are normocalcemic most of the time, but are unable to mount elevated intact parathyroid hormone levels, and therefore unable to correct hypocalcemia, in response to stressors. Genet Med 2008:10(3):224 -228.Key Words: parathyroid hormone, PTH, calcium, Digeorge, 22q11.2, hypocalcemia, hypoparathyroidism, intact PTH Microdeletion of chromosome 22q11 occurs with an incidence of approximately 1/4000 -7000 live births. [1][2][3] This deletion results in failure of development of the derivatives of the 3rd and 4th pharyngeal pouches, with anomalous migration of the cells derived from the cephalic neural crest. 4 Clinical expression varies from one patient to another. Features can include congenital cardiac defects, hypocalcemia, short stature, immunodeficiency from thymic hypoplasia, palate abnormalities, cognitive impairment, and minor facial dysmorphism. 5 Hypocalcemia due to hypoparathyroidism in this population was described originally by Digeorge. 6 The parathyroids are derivatives of the 3rd and 4th pharyngeal pouches, and therefore hypoparathyroidism in this syndrome is not unexpected. It has been documented by aplasia or hypoplasia of parathyroid glands at surgery or autopsy. 7 Our center previously reported hypocalcemia in 77 of 158 (49%) patients. 8,9 Brauner et al. 10 combined a cross-sectional study with historical review to reveal abnormal parathyroid gland function in 69% of patients. However, hypoparathyroidism in 22q11.2 deletion syndrome has been difficult to characterize. The varying degrees of parathyroid dysfunction in the 22q11.2 deletion population, and even intra-individual variation in parathyroid function, have been described by multiple authors. 1,5,10 -15 We hypothesiz...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.